Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

NCT ID: NCT05732272

Last Updated: 2026-01-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 500 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-28
• Study Completion Date: 2027-04-30

Brief Summary

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Detailed Description

The primary objective of this study is to evaluate extended use of bupropion with the goal of enhancing abstinence in African American daily smokers, including the full spectrum of light, moderate, and heavy smokers. A two-arm, randomized design will be used to evaluate the efficacy of extended (6 months) bupropion treatment compared to standard (7 weeks) bupropion treatment. Baseline randomization stratified by gender and cpd (≤10, >10cpd) will assign participants (N=500) to receive extended treatment (EXT; 24 weeks of bupropion, n=250) or standard treatment (ST; 7 weeks of bupropion, n=250). All participants will receive culturally-relevant, individualized smoking cessation counseling, including support for medication adherence, and will be followed through Month 12.

Conditions

Smoking Cessation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard Treatment

250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.

Group Type: ACTIVE_COMPARATOR

Bupropion

Intervention Type: DRUG

150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.

Extended Treatment

250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.

Group Type: ACTIVE_COMPARATOR

Bupropion

Intervention Type: DRUG

150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.

Interventions

Bupropion

150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• African American
• age >18 years
• interested in quitting
• smoked >1 cpd for >1 years
• smoked on >25 days in the past month
• willing to take 6 months of study medication and complete all visits
• have a home address and functioning telephone number

Exclusion Criteria

• Consistent with contraindications for bupropion:
• use of psychoactive medications
• history of alcohol or substance abuse within the past year
• binge drinking (>5 drinks on one occasion) >2 times in the past month
• history of seizures or head trauma; history of bulimia or anorexia nervosa
• pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding
• myocardial infarction in the past 2 months
• reported use of opiates, cocaine, or stimulants
• unstable diabetes
• bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded.
• use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days
• planning to move from the Kansas City area in the next year
• other smoker in household enrolled in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Kansas Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lisa Sanderson Cox, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Kanas Medical Center

Locations

University of Kansas Medical Center

Kansas City, Missouri, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Tricia Snow, MPH

Role: CONTACT

psnow@kumc.edu

816-398-8960

Facility Contacts

Tricia Snow, MPH

Role: primary

psnow@kumc.edu

816-398-8960

Other Identifiers

STUDY00148037

Identifier Type: -

Identifier Source: org_study_id